Judi Charlotte Neuss

This inventor holds 17 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Ucb Pharma, S.a., Katholieke Universiteit Leuven, Ucb Biopharma Sprl. Active years: 2004-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Judi Charlotte Neuss. Retrieved from https://idiyas.com/inventor/judi-charlotte-neuss

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 1)

% Patents Active = 35.3

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 57(Granted Patents)

Location History:

Great Britain, GB (2004)
Oxfordshire, GB (2006)
Slough Berkshire, GB (2013)
Slough, GB (2010 - 2019)
Berkshire, GB (2012 - 2024)

Company Filing History:

Katholieke Universiteit Leuven

Oxford Glycosciences (UK) Ltd

6. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2024

Loading Chart...

Areas of Expertise:

Thiophene Derivatives

Kinase Inhibitors

Fused Bicyclic Heteroaromatic

Pyrimidine Derivatives

Thiazolo-Pyrimidine

Quinoline Derivatives

Thieno-Pyridine

Substituted Aniline

Benzylidene Thiazolidinediones

Antimycotic Agents

Antifungal Agent

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12018021 - Thiophene derivatives for the treatment of disorders caused by IgE (2024-06-25),

2. 10450320 - Hexahydropyrazinotriazinone derivatives as kinase inhibitors (2019-10-22),

3. 10000497 - Fused bicyclic heteroaromatic derivatives as kinase inhibitors (2018-06-19),

4. 9969748 - Fused bicyclic heteroaromatic derivatives as kinase inhibitors (2018-05-15),

5. 9227984 - Therapeutically active fused pyrimidine derivatives (2016-01-05),

6. 9096614 - Therapeutically active thiazolo-pyrimidine derivatives (2015-08-04),

7. 9029392 - Quinoline derivatives as kinase inhibitors (2015-05-12),

8. 8637491 - Thieno-pyridine derivatives as MEK inhibitors (2014-01-28),

9. 8624022 - Substituted aniline derivatives (2014-01-07),

10. 8604051 - Thieno-pyridine derivatives as MEK inhibitors (2013-12-10),

11. 8394822 - Thieno-pyridine derivatives as MEK inhibitors (2013-03-12),

12. 8350037 - Thieno-pyridine derivatives as MEK inhibitors (2013-01-08),

13. 8283359 - Thieno-pyridine derivatives as MEK inhibitors (2012-10-09),

14. 8071582 - Substituted aniline derivatives (2011-12-06),

15. 7678785 - Substituted aniline derivatives (2010-03-16),

Title: **The Innovative Contributions of Judi Charlotte Neuss**

Introduction

Judi Charlotte Neuss, an accomplished inventor based in Slough, GB, has made significant strides in the field of medicinal chemistry. With a remarkable portfolio of 16 patents to her name, her work focuses on developing novel compounds that serve as selective inhibitors for various kinases, ultimately aimed at combating a range of human ailments.

Latest Patents

Among her latest inventions are the "Hexahydropyrazinotriazinone derivatives as kinase inhibitors" and "Fused bicyclic heteroaromatic derivatives as kinase inhibitors." These innovative compounds are designed to selectively inhibit the activity of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ). The implications of these patents are profound, as they showcase the potential to treat and prevent several serious conditions, including inflammatory and autoimmune disorders, oncological diseases, viral infections, malaria, and organ transplant rejection. The versatility of her derivatives, which are substituted in strategic positions to enhance efficacy, highlights her expertise in creating targeted therapeutic solutions.

Career Highlights

Judi has a rich history of professional engagement with notable organizations. She has worked with UCB Pharma, a global biopharmaceutical company, and Katholieke Universiteit Leuven (KU Leuven) in their Research and Development sector. Her tenure at these institutions has provided her with a robust platform to advance her research and contribute to significant biomedical innovations.

Collaborations

Throughout her career, Judi has collaborated with distinguished colleagues, including Daniel Christopher Brookings and Barry John Langham. These partnerships have been instrumental in refining her research and enhancing the development of her patented compounds, fostering a collaborative spirit that underscores the importance of teamwork in scientific advancements.

Conclusion

Judi Charlotte Neuss stands out as a prominent figure in the realm of innovations and patents concerning medicinal therapies. With her extensive experience, impactful patents, and collaborations, she continues to contribute significantly to the scientific community, paving the way for future advancements that can improve health outcomes for patients around the world. Her dedication and inventive spirit exemplify the vital role of inventors in addressing complex health challenges through innovative solutions.

Profile summary based on public USPTO records.